Reduced intensity transplantation: where are we now?

Hematol J. 2004:5 Suppl 3:S34-8. doi: 10.1038/sj.thj.6200419.
No abstract available

Publication types

  • Review

MeSH terms

  • Antineoplastic Agents / adverse effects
  • Antineoplastic Agents / pharmacology
  • Bone Marrow / drug effects
  • Bone Marrow / radiation effects
  • Clinical Trials as Topic
  • Combined Modality Therapy
  • Graft vs Host Disease / prevention & control
  • Hematologic Neoplasms / mortality
  • Hematologic Neoplasms / therapy
  • Humans
  • Immunosuppressive Agents / adverse effects
  • Immunosuppressive Agents / pharmacology
  • Lymphocyte Depletion
  • Myelodysplastic Syndromes / mortality
  • Myelodysplastic Syndromes / therapy
  • Neutropenia / etiology
  • Neutropenia / prevention & control
  • Primary Myelofibrosis / mortality
  • Primary Myelofibrosis / therapy
  • Survival Rate
  • Transplantation Conditioning / adverse effects
  • Transplantation Conditioning / methods*
  • Transplantation Conditioning / trends
  • Transplantation, Homologous / immunology
  • Treatment Outcome
  • Whole-Body Irradiation / adverse effects

Substances

  • Antineoplastic Agents
  • Immunosuppressive Agents